Objectives. Health care guidelines recommend psychological interventions for childhood unusual experiences that are associated with distress or adverse functional impact (UEDs), based on adult, rather than child-specific, evidence. We report the first randomized controlled evaluation of the acceptability and potential clinical utility of cognitive behavioural therapy for childhood UEDs (CBT-UED).
Methods. Participants aged 8-14 years were recruited from referrals to communitypresentations (Poulton et al., 2014) . However, evidence for interventions to date draws primarily on work with adults, rather than exclusively under eighteens. Pilot work shows that offering psychological interventions to younger children with UEDs, to reduce current distress, functional impairment, and, potentially, future mental health risk, is acceptable to children and parents, and may improve current well-being (Maddox et al., 2013) .
Later work has underlined the importance of careful adaptation for children: A recent trial showed that adult-oriented CBT for psychosis (CBTp) may be inferior to nonspecific support for those at the younger extreme of at-risk service intakes (Stain et al., 2016) .
In the current study, we set out to pilot a novel intervention designed for young people (8-14 years) with UEDs (CBT-UED), delivered in addition to usual care, and compared, in a randomized controlled design, to treatment as usual (TAU). The aim was to test whether CBT-UED was a feasible, safe, and potentially helpful addition to TAU that could be evaluated in UK National Health Service CAMHS.
Method
Participants Participants aged 8-14 years were recruited to the Coping with Unusual Experiences Study (CUES, ISRCTN 13766770) from referrals to community CAMHS for young people with emotional and behavioural problems that did not usually reach criteria for formal psychiatric diagnosis. We recruited 'clinically referred', rather than 'help-seeking' children, as, at this age, help is usually sought by parents or schools. The study comprised a baseline screening and assessment phase, with a second phase of participation in the trial offered only to young people meeting screening criteria, that is, those reporting a UE with emotional symptoms in the borderline or clinical range, assessed by the Strengths and Difficulties Questionnaire (SDQ, Goodman, 2001) . Service clinicians routinely triaged new referrals: Those requiring specialist treatment for a severe mental illness, a specific clinical disorder, or a neurological condition were referred on, and those requiring urgent care were seen immediately. Non-urgent, appropriate referrals were placed on a waiting list for further assessment and treatment, and sent information about the study. We excluded from screening and baseline assessment only participants who (1) required specialist services (on subsequent assessment); (2) had insufficient written or spoken English ability to complete assessments; or (3) were likely to move away from the local area over the next 6 months, and thus not be able to complete participation in the trial.
Measures
Demographic and developmental characteristics Age, gender, ethnicity, developmental history (speech/motor delay or current motor problem, Laurens et al., 2007) , and family history of mental illness were reported by primary caregivers. Ethnicity was coded dichotomously (BME: any black or minority ethnic group; non-BME: white British or Irish). General intelligence (IQ) was approximated from British Picture Vocabulary Scale standardized scores (BPVS II, Dunn, Dunn, Whetton, & Burley, 1997) .
Strengths and Difficulties Questionnaire (SDQ, Goodman, 2001) We used a self-report SDQ, suitable for screening 8-to 17-year-olds for internalizing and externalizing emotional and behavioural difficulties characteristic of childhood (Goodman, Lamping, & Ploubidis, 2010; Goodman, Meltzer, & Bailey, 1998; Muris, Meesters, & van den Berg, 2003) . Four subscales, each of five items rated 0 (not true), 1 (somewhat true), or 2 (certainly true), assess internalizing (Emotional Symptoms, Peer Relationship Problems) and externalizing (Hyperactivity/Inattention, Conduct Problems) problems. Higher scores indicate greater difficulty. Subscale scores (0-10) combine to form a Total Difficulties score (0-40), assessing general childhood psychopathology. Five items, excluded from the total score, assess Prosocial Behaviour. The Emotional Symptoms subscale (SDQ-ESS, proposed primary outcome) measures symptoms (such as feeling 'nervous', 'scared', 'tearful', 'worried', 'sick') associated with low mood and anxiety. Borderline or clinical scoring (≥6) at baseline was a screening criterion for study inclusion and objective justification for offering therapy. Reliable change (i.e., of greater magnitude than the expected measurement error of the instrument, Jacobson & Truax, 1991) was calculated using the population standard deviation (SD) of 2.1 (Goodman, 2001 ); improvement to a score <6 was taken as clinically significant change. General childhood psychopathology (SDQ-Total Difficulties, including SDQ-ESS) was a secondary outcome.
Unusual Experiences Questionnaire (UEQ; Ames et al., 2014; Laurens, Hobbs, Sunderland, Green, & Mould, 2012; Laurens et al., 2007) This nine-item, self-report questionnaire assesses unusual perceptions and ideas, incorporating five items adapted from the Diagnostic Interview Schedule for Children (DIS-C; Costello, Edelbrock, Kalas, Kessler, & Klaric, 1982) with good internal consistency and validity (Laurens et al., 2012) . Items are endorsed on a 3-point Conviction scale: 0 (not true); 1 (somewhat true); and 2 (certainly true). We used an adapted version (Ames et al., 2014) so that endorsed UEs were also rated for Frequency over the past 2 weeks: 0 (not at all); 1 (only once); 2 (2-4 times); 3 (5+ times); Distress ('How much has it upset you?') and adverse functional Impact ('How much has it made things hard at home or school?'), both rated: 0 (not at all); 1 (only a little); 2 (quite a lot); and 3 (a great deal). Item totals (ratings across dimensions of conviction, frequency, distress, and impact: range 0-11) were summed to create a total severity score, and, by selecting only those items where distress or impact was rated >0, a total UED-severity score. Dimension ratings were summed across items to create total conviction (0-18), frequency (0-27), and combined distress/impact (0-54) scores (Ruffell et al., 2015) . Secondary UE outcomes for this study comprised the following: the number of UEs endorsed as somewhat or certainly true (UEnumber, 0-9); the number of UEs endorsed with distress/adverse impact >0 (UEDnumber, 0-9); UE-frequency (total frequency dimension scores, 0-27); UE-D&I (combined distress/impact dimension scores (0-54); and UED-severity (0-99). Higher scores indicated greater severity. Endorsing any UE as somewhat or certainly true (UEnumber ≥1) was the second screening criterion for trial inclusion.
Short Mood and Feelings Questionnaire (SMFQ; Angold et al., 1995) The 13-item SMFQ provided a secondary measure of childhood depression, more detailed and specific than the SDQ-ESS. Symptom presence over 2 weeks is self-rated 0 (not true), 1 (sometimes true), or 2 (true), with a cut-off of ≥8. Convergent validity, sensitivity, and specificity are good (Angold et al., 1995) . Spence Children's Anxiety Scale (SCAS, Spence, 1998) The 44-item SCAS provided a secondary, detailed measure of childhood anxiety. Symptoms of generalized anxiety, panic/agoraphobia, social phobia, separation anxiety, obsessive compulsive disorder, physical injury fears, plus six unscored filler items, are selfrated for frequency: 0 (never); 1 (sometimes); 2 (often); or 3 (always). The SCAS is validated in 8-to 15-year-olds; normative mean score across gender and age ranges is 27.4 (SD = 16.5); scores of 40+ are considered to be in the clinical range and represent the most anxious 16% of the population (Essau, Sasagawa, Anastassiou-Hadjicharalambous, Guzm an, & Ollendick, 2011; Spence, Barrett, & Turner, 2003) .
Study design
Participants were randomly allocated, in a 1:1 ratio, to one of two arms, receiving the CUES intervention immediately (CBT-UED) or after 12 weeks (TAU/WL). Randomization was carried out by the Clinical Trials Unit of King's College London, employing blocks of randomly varying size, stratified by gender. Usual CAMHS treatment continued irrespective of allocation, without any interference from the research team, and was documented for all participants. We calculated the sample size needed to estimate 95% confidence intervals (CIs) with a margin of error (ME) of AE10% for three key trial parameters: retention rate once recruited (estimated 80%); rate of positive screens (estimated 50%); and rate of consent to screening (estimated 50% of those approached). A sample of n = 60 eligible participants was required to estimate retention rates, indicating a need to screen n = 120 (95% CI, ME AE 9%), and to approach n = 240 (95% CI, ME AE 6%). Sample size recommendations for estimation of variance range from 24 to 50 participants (Julious, 2005; Sim & Lewis, 2012) .
Procedure
The study was approved by the London-Hampstead Committee of the United Kingdom National Research Ethics Service (ref. 11/LO/0023) and conducted in accordance with the Declaration of Helsinki (World Medical Association, 2013) . Study information packs explaining the two parts of the study (baseline assessment/ screening, followed by the treatment evaluation for young people with UEDs) were mailed to parents, with an age-adapted young person's version and assent form. A trained researcher explained the study to families who expressed interest in participating and sought parental consent and child assent. Consented participants completed screening (UEs and emotional symptoms) and baseline (depression, anxiety, and childhood psychopathology) assessments, at their school, home, or CAMHS clinic depending on convenience for the family. Children used a bespoke online survey (SelectSurvey.NET 2.8.5), with researcher support as needed; parents completed paper questionnaires. Young people meeting screening criteria (UE-number ≥1; SDQ-ESS ≥6) were invited to participate in the randomized controlled trial (RCT). Post-treatment measures were completed at 12 weeks, irrespective of therapy completion. After 12 weeks, the TAU/WL participants were offered therapy. All participants completing therapy were re-assessed 4 weeks after their final therapy session ('1-month post-therapy'). At the request of participating services, families who agreed to future contact were re-contacted for an opportunistic uncontrolled follow-up, 1-4 years after their baseline assessment ('1-to 4-year follow-up'), at which the SDQ and UEQ were re-administered. The trial was registered retrospectively (statutory registration of pilot studies was introduced after study commencement), but the design was unchanged from the funding application and registration preceded completion of recruitment, data collection, and analysis. The trial protocol is available upon request from the authors; the CONSORT checklist is included in Appendix (Eldridge et al.., 2016; Moher et al.., 2010) .
Intervention
The CBT-UED intervention comprised 9-12 individual sessions, each of 40-to 50-min duration, usually delivered weekly. Therapy was adapted from adult CBTp interventions, drawing on pre-pilot work and both young person and parent consultation (Browning, Corrigall, Garety, Emsley, & Jolley, 2013; Maddox et al., 2013;  Table 1 ). The intervention was manualized, with sessional plans, interactivities, between-session tasks, and co-produced, developmentally appropriate handouts. Therapy was delivered by the manual co-creator, KB, an experienced CAMHS nurse with post-graduate qualifications in CBT, and CBTp. Supervision was provided by SB, the lead author of the manual and CAMHS consultant clinician, trainer, and trial therapist. Therapy adherence was rated by KB and SB using a sessional activity checklist. Four raters, independent of therapy delivery, assessed 16 sessions (of 140 completed with 21 participants, 11%), using a comprehensive checklist of CBT and CBTp activities. Raters agreed on 88% of competence ratings and 90% of presence ratings, with no session rated as not competent (Nasseri, 2015) .
Statistical analysis
Analyses were performed using the Statistical Package for the Social Sciences (SPSS, v.22; IBM Corp, 2013) and STATA version 14.0 (Statacorp, 2015) . Baseline characteristics were summarized using descriptive statistics. Acceptability of trial procedures was examined using proportions and 95% CIs (consent to screening, target 50%; eligibility, target 50% of those screened; retention, target ≥80%; we anticipated a recruitment rate of three participants/month from 28 new referrals). Acceptability of treatment was judged by uptake, sessions attended, and retention. Potential helpfulness was judged by the proportion of young people showing reliable or clinically significant improvement on the SDQ-ESS in the intervention group compared to the control group, with odds ratios (ORs) transformed to between-group effects (d) using the Logit method. ORs were also calculated for other categorical outcomes (meeting trial screening criteria; UE-number ≥1/ <1; UED-number ≥1/<1). Emphasis was placed on CIs of effect size estimates, rather than hypothesis testing, allowing for exploration of imprecision around effect sizes. As therapy was ongoing but incomplete (<12 sessions) for most participants at 12 weeks, we created, post-hoc, an end-of-treatment (EOT) outcome, using 1-month post-therapy scores for young people who were allocated to, but had not completed, therapy at 12 weeks, and the 12-week score for all other young people.
Missing data
Scores for multi-item measures were classified as missing data if three or more items were incomplete, and prorated otherwise. One TAU/WL participant withdrew consent to use their data. One TAU/WL and three CBT-UED participants missed the 12-week assessment. We analysed proposed primary SDQ-ESS and secondary UE scores under the missing at random assumption (White, Horton, Carpenter, & Pocock, 2011) . Predictors of missingness were identified using a series of random intercept logistic regression analyses. We investigated age, gender, ethnicity, IQ, baseline SDQ-ESS, UED-severity, and SDQ-Total, allocation, and time of assessment (baseline or 12 weeks). For the 1-to 4-year follow-up, we additionally investigated age at follow-up and length of time from randomization to follow-up. None of the variables significantly predicted missing data at 12 weeks or follow-up (z scores all <1.8, p values all >.08); therefore, we assume missing completely at random and no additional variables were controlled in subsequent analyses.
Treatment effect estimation
Non-categorical clinical outcomes were analysed on an intention-to-treat basis using a random intercept logistic regression analysis, comparing outcomes at 12 weeks and EOT between the CBT-UED and TAU/WL conditions, with baseline outcome measures as a covariate. The same analyses were repeated for the proposed primary outcome (SDQ-ESS) and for each secondary outcome variable (UE-number; UED-number; UEfrequency; UE-D&I; UED-severity; SDQ-Total; depression; anxiety). Between-group treatment effects (d) were also calculated as the difference in mean change between groups, divided by SD, adjusted for the degree of association between pre-and postscores. To estimate sample size for future studies, 95% CIs for treatment effects were recalculated for key outcomes, using the upper limit of the 80% CI as a robust estimate of variance.
Additional analyses
As this was a pilot evaluation of a novel intervention, changes in primary and secondary outcomes within each allocation group were also examined for each time Completed opportunistic 1 to 4 year follow-up (n = 19) (n = 13 aŌer 1-month assessment; n = 3 completed therapy but missed 1-month assessment (2 TAU, 1 CBT); n = 3 not completed therapy (TAU (n = 2): clinical need (n = 1); declined (n = 1); CBT (n = 1, dropped out at 4 sessions)
Of 49 allocated, n = 7 declined future contact when asked, n = 12 could not be contacted; n = 11 were contacted but declined to aƩend, due to Ɵme (n = 3) or no problems (n = 5) Potential predictors of therapy completion (age, gender, ethnicity, IQ, allocation, and SDQ-ESS, UED-severity, and SDQ-Total scores, each at baseline and 12 weeks) were examined using a series of random intercept logistic regression analyses.
For the 1-to 4-year follow-up, Pearson's correlations were employed to examine the association with outcomes of participant age at follow-up and time from randomization to follow-up, calculated with and without adjustment for initial allocation. To assess durability of changes following treatment, pre-post-effect sizes were estimated for withinparticipant change from baseline to 1 month post-therapy and to 1-to 4-year follow-up (durability indicated by comparable changes), and from 1 month post-therapy to 1-to 4-year follow-up (durability indicated by the absence of deterioration).
Results

Participant flow
The CUES project recruited from May 2011 to April 2014; follow-ups were completed by January 2016. Participant flow is illustrated in Figure 1 . Of around 1,000 expected referrals to the service (average 28/month over 36 months), 304 (30%; 95% CI: 27-33%) were identified to the research team as potential contacts, 174 (57%, 95% CI: 51-63%) met age criteria and were successfully contacted, and 110 (63%, 95% CI: 59-67%) consented to participate. Ninety-six completed screening (55% of those contacted, 95% CI: 48-62% [target: 50%]; 87% of those consenting, 95% CI: 81-93%). Of 51 meeting screening criteria (53%, 95% CI: 43-63% [target: 50%]), all but two (96%; 95% CI: 91-100%) agreed to randomization (24 to CBT-UED; 25 to TAU/WL). Actual recruitment rates were slower than estimated, necessitating an extension to recruitment (2.7/month recruitment to screening [target: 6/month]; 1.4/month meeting screening criteria [target: 3/month]). Fortyfour participants completed 12-week outcomes (90% (95% CI: 82-98%); 21/24 CBT-UED, 23/25 TAU/WL).
Baseline demographic and clinical characteristics
Young people meeting screening criteria had higher scores on all outcome measures, and lower IQ scores than those not meeting screening criteria, with mean SDQ-Total, anxiety, and depression scores in the clinical range (Table 2) . Screening positive was not associated with age, ethnic background, family/parental history of mental illhealth, or history of developmental problems. Young people not meeting screening criteria were more likely to be male. Amongst trial participants, SDQ-Total (r = .4, p = .008, n = 48) and depression (r = .4, p = .01, n = 46) scores were higher in older children. Girls, compared to boys, reported more depression (r = .4, p = .02, n = 46). Lower IQ was moderately associated with higher SDQ-ESS, UE-frequency, UE-D&I, and anxiety scores (r values .3-.5, p values <.05). All other r values were <.3, p > .05.
Adverse events
We classified as a potential adverse event any deterioration in the young person's mental health or welfare that was noted by the young person, family/responsible adult, clinical team, or study team. Any such event judged by any of these parties as 100% (24) 100% (48) 14% (7) 3 v 2
(1) = 74.5*** UE present 100% (24) 100% (24) 100% (48) 64% ( related to study participation was considered to be an adverse event and was rated for severity according to the degree of adverse impact upon the young person. Three potential adverse events were identified, all by the study team. Two occurred in the TAU/WL group: a non-fatal overdose, and an identified social care need, resulting in withdrawal of consent. One occurred in the CBT-UED group: readmission to psychiatric hospital following relapse of a pre-existing, relapsing mental health condition. No event was considered by the young person, family, treating team or study team to represent a change in presentation arising because of study participation (although the identification of the social care need occurred because of participation, the need itself did not). In each case, the study team was closely involved in facilitating appropriate care.
Therapy completion at 12 weeks
Of the 21 CBT-UED participants completing a 12-week assessment, four (19%, 95% CI: 10-28%) elected to discontinue therapy early after five to seven sessions. One more attended only five sessions over 12 weeks and was referred by the treating team to a specialist service after the 12-week assessment. The remaining 16 had only completed just over half of their therapy sessions by 12 weeks (mean 7.1, SD = 2.0; range 4-11 sessions); 60% (range 30-90%) of the total received by therapy completion (mean 11.9, SD = 1.4, range 10-14 sessions). Of the three participants not completing a 12-week assessment, one was lost to follow-up before starting therapy, one received two sessions before being admitted to hospital and withdrawing from the study, and one received six sessions, before being transferred to a specialist service and subsequently lost to follow-up.
Therapy uptake after waitlist control
Of the 23 TAU/WL participants offered therapy after completing the 12-week assessment, 19 took up the offer and four declined. Of those taking up the offer, 17 of 19 engaged in a full course of therapy (mean 11.2, SD = 1.7, range 8-14 sessions); one started, but was referred to another service after seven sessions and was then lost to follow-up; and one attended one session only and then dropped out.
Predictors of therapy completion
Age, gender, ethnicity, IQ, allocation, and SDQ-ESS, UED-severity, and SDQ-Total scores at baseline and at 12 weeks were investigated as potential predictors of therapy noncompletion using a series of random intercept logistic regression analyses. Only SDQTotal at baseline was a significant predictor (Coefficient = .2, p = .02, 95% CI: 0.03-0.4, otherwise z scores all <1.1 p values all >.3). Post-hoc examination revealed significant subscale differences only for Conduct Problems (non-completers mean 4.8, SD = 2.3, n = 15; completers mean 3.0, SD = 1.9, n = 33; t = 2.8, df = 46, p = .007; else, t values <1.7, p values >.1).
Usual care
Usual care was not documented for the five young people who withdrew consent or were lost to follow-up; no data were available for one further TAU/WL participant. For the remaining participants (n = 21 CBT-UED, n = 22 TAU/WL) usual care ranged from no *p < .05; **p < .01; ***p < .001 -significance levels derived from within group paired t-test of pre-post-scores or between-group independent-samples t-test of change scores.
contact (n = 8 CBT-UED, n = 9 TAU/WL), through one-off assessment/review without intervention (n = 3 CBT-UED; n = 3 TAU/WL), to regular meetings with specialist CAMHS practitioners for support tailored to referral problems (n = 10 CBT-UED; n = 10 TAU/WL).
Does the CBT-UED therapy show potential to improve outcomes compared to usual care?
The proportion of participants showing reliable change (exceeding expected measurement error, Jacobson & Truax, 1991) and clinically significant change (to a non-clinical score, <6) on the SDQ-ESS at 12 weeks and EOT was compared between the CBT-UED group and the TAU/WL group, with ORs transformed to d values using the Logit method.
No participant showed reliable deterioration. A non-significantly higher proportion of the CBT-UED group showed reliable improvement (29% CBT-UED; 13% TAU/WL, d (Logit) = 0.6, 95% confidence interval [CI]: À0.02 to 1.2) and clinically significant improvement (from above to below the borderline/clinical threshold; 52% CBT-UED; 39% TAU/WL, d(Logit) = 0.3, 95% CI: À0.3 to 0.9). Allocation groups did not differ significantly on any categorical outcome at either 12 weeks or EOT, v 2 values < 1.0 (df = 1), p values >.5, and ORs are shown in Table 3 .
Continuous outcomes were analysed on an intention-to-treat basis using a series of random intercept logistic regression analyses, comparing each outcome firstly at 12 weeks, then at EOT, between the CBT-UED and TAU/WL conditions, with baseline score as a covariate.
Treatment effects (lower score, better outcome) were very small at 12 weeks for the proposed primary SDQ-ESS outcome (Coeff. = À.1, p = .9, 95% CI: À1.5 to 1.3), and for all secondary UE and other outcomes (z scores all <1.0, p values all >.3). At EOT, treatment effects were larger: No significant differences were found for SDQ-ESS (Coeff. = À.4, p = .6, 95% CI: À1.7 to 0.9), but there were group differences on the secondary UE measures at EOT, reaching statistical significance for UED-severity (Coeff. = À6.8, p = .04, 95% CI: À13.3 to À0.2), with a trend for UED-number (Coeff. À1.0, p = .07, 95% CI: À2.2 to 0.07) and UE-D&I (Coeff. = À2.6, p = .07, 95% CI: À5.4 to 0.3; otherwise z scores all <1.3, p values all >.2). Group means and between-group treatment effects (d) are shown in Table 4 .
Within group, pre-post-changes are also shown in Tables 3 and 4 , showing no deterioration in either group, and overall small pre-post-changes within the TAU/WL group (on SDQ-ESS, two UE measures, and SDQ-Total [t values >2.0, p < .05], and all categorical outcomes, but not UE-frequency, UE-number or UED-number, anxiety or depression [t values <0.2, p > .05]), and larger pre-post-changes within the CBT-UED group, particularly at EOT (significant t values >2.5, p values <.05; else t values <2.5, p values >.05), except on depression, which did not change (t value <1.0, p value >.4).
Do changes persist?
Young people (n = 19) completed 1-to 4-year follow-up assessments at a mean of 2.5 years (SD = 0.9, range 1.3-3.8) after randomization. Longer time to follow-up was associated with fewer UEs (r = À.6, p = .01) and fewer UEDs (r = À.6, p = .01), irrespective of controlling for initial allocation (otherwise, r values ranged from .1 to À.3, p values >.1). Mean age at follow-up was 14.1 years (SD = 2.3, range 10.2-18.7). Age was unrelated to any outcome score, irrespective of initial allocation (r values ≤ .3, p values (14) (51-71%)
.004 100% (21) 48% (10) (37-59%) .001 48% (10) (37-59%)
.001 1.7 (0.5-5.7) 1.7 (0.5-5.7) SCREEN+ve 100% (23) 52% (12) (42-62%)
.001 100% (21) 48% (10) (37-59%) .001 43% (9) Ethnicity BME/non-BME *p < .05; **p < .01; ***p < .001 -significance levels derived from within group paired t-test of pre-post-scores.
>.1). Effect size estimates, comparing scores from baseline to 1-month post-therapy to 1-to 4-year follow-up, showed small deteriorations from the 1-month post-therapy assessment, and persisting improvement compared to baseline. For categorical outcomes, by 1-to 4-year follow-up, although UE/UED rates had increased, associated SDQ-ESS scores were not in the clinical range (Table 5) .
Variance estimates for future power analyses Treatment effects and 95% CIs were recalculated for the SDQ-ESS categorical outcomes (reliable improvement and clinically significant improvement) using the upper limit of the 80% CI for the standard error of ORs, transformed to d values using the Logit method, and for the SDQ-ESS and UED-severity baseline and EOT mean scores, using the bootstrapped upper 80% CI limit for the standard deviation. Treatment effects ranged from d = 0.2 to 1.3 for SDQ-ESS reliable improvement; from d = 0.3 to 0.8 for SDQ-ESS clinically significant improvement; from d = À0.3 to 0.9 for SDQ-ESS mean score; and from d = 0.1 to 1.1 for UED-severity mean score. These estimates suggest sample sizes from n = 176 to in excess of 500 participants to reliably (with 95% power, a = .05) evaluate betweengroup change in SDQ-ESS, and of n = 110 to evaluate change in UED-severity.
Discussion
We evaluated whether our novel CBT-UED intervention, adapted specially for children, was feasible, safe, and a potentially helpful addition to usual community CAMHS care. Following treatment recommendations, clinical distress (emotional symptoms) was the proposed primary outcome. We also measured change in unusual experiences, employing a range of indices to determine the most useful measurement for clinical purposes and potential future evaluation. The study was well-received by services, parents, and young people. Screening and assessment procedures were developmentally appropriate, with good completion in our frontline setting. However, assessors needed skills in engagement and in managing the challenge of balancing interactivity/play with task-focused activity. The two-stage design was acceptable to participants and their families. The randomization procedure was unproblematic. The CBT-UED intervention was feasible to implement and positively received across the board. No adverse events were causally attributed to the therapy or assessments. Retention at 12 weeks was good. Over half of participants and families were uncontactable for the opportunistic 1-to 4-year follow-up, possibly reflecting our mobile inner-city population. Higher levels of childhood psychopathology, and potentially particularly Conduct Problems, were associated with therapy non-completion. Further investigation of this is needed: Alternative approaches may better suit externalizing problems.
Screening suggested that around half of CAMHS referrals have a UE with clinical/ borderline distress on the SDQ-ESS and could be offered intervention. However, as treatment guidance specifies self-reported distress, without clinical criteria, rates may in practice be higher: All but one trial participant self-reported distress/impact on the UEQ, but 19 young people (17% of those screened) reported a UED with SDQ-ESS < 6, and were excluded. Selection and screening methods may therefore require further investigation to ensure the target population is accessed. While the proportion of young people and their families agreeing to screening and meeting eligibility criteria was within the target range, the recruitment rate was less than half of that predicted, with only a third of referrals put forward to the research team, and only half of these contactable. Clinician feedback indicated that, rather than asking all referrals about the research, and two-thirds having refused contact, they were inadvertently pre-selecting potentially suitable participants to ask. Routine screening in services may circumvent this difficulty and facilitate investigation of barriers to access.
Therapy was well-delivered, as expected from expert clinicians, but the time needed to complete therapy exceeded 12 weeks in nearly every case, and one or two extra sessions (14 sessions in total) were required for several cases to cover the manualized therapy content. The additional input appeared to be useful as outcomes improved slightly between 12 weeks and EOT, and may reflect the greater complexity of difficulties in this CAMHS setting compared to a general population case series. A longer course of therapy, and an additional month to complete therapy, would improve future studies in clinical contexts.
The range of estimated treatment effects generally slightly favoured the CBT-UED group, for all outcomes except depression and SDQ-Total, and particularly for UE outcomes. There was no suggestion that the CBT-UED intervention caused harm, and some positive change with TAU/WL. Between-group SDQ-ESS differences were smaller than anticipated (d = 0.3-0.6), indicating a substantially larger sample size for a future, similar analysis with adequate power to detect between-group differences. UED betweengroup differences were larger, but baseline scores differed markedly, despite random allocation, with unknown impact on the likelihood and magnitude of change. Findings suggest that CBT-UED may have most potential to augment usual CAMHS care by improving UE-specific outcomes, rather than general psychopathology. Of the UE outcomes, UED-severity changed most consistently and, pending replication, may be an appropriate primary outcome in future studies, particularly given its role in influencing future trajectories (Lin et al., 2011) . In their feedback, young people particularly noted the helpfulness of normalizing information about coping with UEDs and suggested that this could usefully be provided from an early age in schools, as they wished they had understood their own experiences sooner.
The gains made during any treatment were somewhat durable: Only a third of participants still met screening criteria at the 1 month post-therapy and 1-to 4-year followups, with small, non-significant between-group differences at EOT favouring CBT-UED (43% vs. 52%). While UEs and UEDs had partially returned by follow-up, reductions in severity and clinical distress persisted, potentially reflecting more adaptive ways of responding.
Limitations
Several issues should be considered in interpreting findings. The study was a pilot, not powered to detect treatment effects, and multiple comparisons were conducted without correction. We recruited from a single inner-city UK NHS Trust: Findings may be contextspecific. Longer term follow-up assessments were uncontrolled, so cannot inform estimates of treatment effects, and all assessments were conducted unblinded, potentially inflating effects. Only half of participants could be contacted for the opportunistic 1-to 4-year follow-up, potentially biasing the sample, although attendance was not associated with baseline demographic or clinical variables. Alternative follow-up methods, that do not require contacting families (e.g., primary care records), could mitigate bias in future studies, with provision made to obtain the young person's ongoing consent (in addition to their original assent to parental consent) once they reach 16 years.
Conclusions
Around half of children presenting to CAMHS with emotional and behavioural difficulties may also have a UED warranting an offer of intervention. Our findings indicate that while routine care has a small impact in improving UEDs, a novel therapy specifically targeting these experiences in childhood was feasible and safe to deliver, and may augment standard care. Further evaluation is required. Key issues to consider in future research are the selection criteria for participants; the choice of primary outcome and consequent sample size implications; the time frame to deliver therapy; and the logistics of following up young people living in an inner city setting over a longer time period.
Introduction
Background and objectives We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomized trials, noninferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see www.consort-statement.org.
